(Q45733718)

15 December 2017

title

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma (English)

1 reference

15 December 2017

10

B Roizman

1 reference

15 December 2017

S-M Chung

1

1 reference

15 December 2017

S J Advani

2

1 reference

15 December 2017

J D Bradley

3

1 reference

15 December 2017

Y Kataoka

4

1 reference

15 December 2017

K Vashistha

5

1 reference

15 December 2017

S Y Yan

6

1 reference

15 December 2017

J M Markert

7

1 reference

15 December 2017

G Y Gillespie

8

1 reference

15 December 2017

R J Whitley

9

1 reference

15 December 2017

R R Weichselbaum

11

1 reference

15 December 2017

publication date

1 January 2002

1 reference

15 December 2017

1 reference

15 December 2017

volume

9

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

75-80

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Genetically engineered HSV in the treatment of glioma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

7 January 2021

Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301620

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301620

1 reference

Dimensions Publication ID

15 December 2017

1019353382

0 references

1 reference